1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On June 8, 2026, Ingredion agreed with Tate & Lyle's board on a recommended all-cash acquisition of Tate & Lyle at 595 pence per share, with cash consideration of about £2.7 billion (about $3.6 billion) and an implied enterprise value of about $5.0 billion. Ingredion plans to fund the deal with existing cash, new debt and, if needed, a 364-day bridge loan, and expects pro forma net leverage of about 3.0x net debt-to-adjusted EBITDA at completion. The deal is expected to close in the second half of 2027, subject to Tate & Lyle shareholder and court approval and antitrust conditions, and Ingredion expects it to be adjusted EPS accretive in the first year.
Tate & Lyle shareholders would receive 595 pence in cash per share, about a 59% premium to the May 13, 2026 closing price.
Cash consideration is about £2.7 billion (about $3.6 billion); implied enterprise value is about £3.7 billion ($5.0 billion).
Ingredion expects pro forma net leverage of about 3.0x at completion and about 2.5x within about 18 months.
Expected run-rate net cost synergies of about $130 million by the end of 2030, against one-time costs of about $175 million.
Lakeland Industries reported fiscal first quarter 2027 results for the period ended April 30, 2026. Net sales rose 1.4% to $47.4 million and net income was $0.4 million, compared with a net loss of $3.9 million a year earlier, but the profit swing reflects a $6.5 million gain on the sale of HPFR and HiViz product lines, while gross profit fell 4.9%.
Net sales were $47.4 million, up $0.7 million or 1.4% from $46.7 million in Q1 FY26.
Gross profit was $14.9 million, down $0.8 million or 4.9% from $15.6 million.
Net income was $0.4 million versus a net loss of $3.9 million, and the reconciliation includes a $6.5 million gain on sale of certain assets recorded in March 2026.
Adjusted EBITDA excluding FX was $1.1 million, compared with $0.6 million; borrowings under the revolving credit facility were $23.8 million as of April 30, 2026.
Cracker Barrel reported fiscal third-quarter 2026 revenue of $797.4 million, down 2.9% from a year earlier, and GAAP diluted earnings of $1.90 per share, which include a $47.4 million litigation settlement benefit. Excluding non-GAAP adjustments, adjusted diluted earnings were $0.29 per share versus $0.58 a year earlier, and adjusted EBITDA was $40.3 million versus $48.1 million. The company raised its fiscal 2026 revenue and adjusted EBITDA outlook, which is the main positive for shareholders.
Q3 total revenue $797.4 million, down 2.9%; comparable store restaurant sales down 2.6%
GAAP diluted EPS $1.90 vs $0.56; adjusted diluted EPS $0.29 vs $0.58
Fiscal 2026 adjusted EBITDA outlook raised to $120 million to $125 million from $85 million to $100 million
Fiscal 2026 revenue outlook raised to $3.27 billion to $3.30 billion from $3.24 billion to $3.27 billion
Perma-Pipe reported first-quarter fiscal 2026 results for the quarter ended April 30, 2026. Net sales rose 7.5% to $50.3 million, but gross profit fell to $14.6 million from $16.7 million, and net income attributable to common stock fell to $1.8 million from $5.0 million, which management attributed partly to Middle East project delays and start-up costs. Management still expects revenue and net income growth for fiscal 2026 compared with fiscal 2025.
Net sales were $50.3 million, up from $46.7 million a year earlier, driven by higher volumes in North America and MENA.
Net income attributable to common stock was $1.8 million, versus $5.0 million; diluted EPS was $0.22, versus $0.61.
Backlog reached $136.5 million at April 30, 2026, up about 12% from $121.6 million at January 31, 2026.
Management said no projects have been cancelled and still expects revenue and net income growth for fiscal 2026.
Titan Machinery reported fiscal first-quarter 2027 results for the three months ended April 30, 2026. Revenue fell to $522.4 million from $594.3 million, while the net loss narrowed to $12.6 million, or $0.55 per diluted share, from $13.2 million, or $0.58 per share. The company reaffirmed its fiscal 2027 modeling assumptions, which include an adjusted diluted loss per share of ($1.25) to ($1.75), so shareholders see a smaller loss against weaker sales and continued expected losses for the year.
Revenue was $522.4 million versus $594.3 million a year earlier; Europe revenue fell 35.6% and Agriculture revenue fell 10.4%.
Net loss was $12.6 million, or $0.55 per diluted share, compared with a net loss of $13.2 million, or $0.58 per share.
Gross profit margin rose to 17.1% from 15.3%, while adjusted EBITDA was $1.0 million versus $2.6 million.
Fiscal 2027 guidance was reaffirmed, with adjusted diluted loss per share expected at ($1.25) to ($1.75); net cash used for operating activities was $23.1 million.
J.M. Smucker reported fourth-quarter fiscal 2026 net sales of $2.3 billion, up 6%, and adjusted earnings per share of $2.77, up 20%. For the full fiscal year, adjusted EPS fell 10% to $9.15 and the company posted a net loss of $1.30 per diluted share, while it guided fiscal 2027 net sales down 3.0% to 4.0% and adjusted EPS of $9.75 to $10.25.
Q4 net sales $2.3 billion (about $2,268.1 million), up 6%; adjusted EPS $2.77 vs. $2.31 a year earlier.
Q4 GAAP net income $3.64 per diluted share, compared with a net loss of $6.85 in the prior-year quarter, which included $867.3 million of goodwill impairment charges.
Fiscal 2026 net sales $9.1 billion, up 4%; net loss of $1.30 per diluted share; adjusted EPS $9.15, down 10%.
Fiscal 2027 outlook: net sales down 3.0% to 4.0%, adjusted EPS $9.75 to $10.25, free cash flow about $1.0 billion.
UNFI reported third-quarter fiscal 2026 results for the 13 weeks ended May 2, 2026. Net sales fell 4.2% to $7.7 billion, which the company said included about 450 basis points of impact from optimization actions, while net income rose to $33 million from a $7 million loss a year earlier. The company reiterated its full-year fiscal 2026 outlook midpoints and narrowed the ranges, and reported net leverage of 2.5x.
Net sales decreased 4.2% to $7.7 billion, including about 450 basis points of impact from optimization actions
Net income of $33 million, or $0.52 per diluted share, versus a net loss of $7 million, or $0.12 per share, a year earlier
Adjusted EBITDA rose 16.6% to $183 million; free cash flow was $54 million versus $119 million
Fiscal 2026 outlook midpoints reiterated for net sales, net income, EPS, Adjusted EBITDA and Adjusted EPS, with ranges narrowed
Novanta agreed on June 8, 2026 to acquire Riverpoint Medical from Arlington Capital Partners for $1.2 billion in cash at closing, plus a $250 million milestone payment due by January 8, 2027. The deal is funded with cash on hand, existing credit facilities and a $300 million equity raise, and the credit agreement was amended to raise the permitted leverage ratio, which means more debt for shareholders to carry. The company expects the deal to close in the third quarter of 2026 and says it will update guidance after closing.
Purchase price of $1.2 billion in cash at closing, subject to customary adjustments, plus a $250 million milestone payment due on or before January 8, 2027
Financing from cash on hand, existing credit facilities and a recently completed $300 million equity raise
Credit agreement amended: permitted consolidated leverage ratio raised to 4.00 to 1.00, or 4.50 to 1.00 for four quarters after a designated acquisition
Expected net leverage of about 2.7x at closing in the third quarter of 2026, with a target below 2.3x by year-end 2027; standalone 2026 guidance was confirmed
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.